Fosamax Osteonecrosis of the Jaw Prognosis: Long-Term Outcome After Exposure

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Inquiry

The legacy of general health and science information has long provided a foundation for public understanding of medical conditions and their management. Within this broad context, the dissemination of knowledge about bone health and the use of medications to address osteoporosis has been a key focus. This heritage includes discussions of therapeutic options, their intended benefits, and the importance of informed patient decision-making. As this informational landscape evolves, a natural progression emerges toward examining specific, clinically significant outcomes associated with long-term medication use. One such area of concern involves the potential for adverse effects that may arise from sustained exposure to certain pharmaceutical agents. This shift in focus moves from general health education to a more targeted inquiry into the consequences of drug therapy. Specifically, the transition leads to an examination of the prognosis for patients who have developed osteonecrosis of the jaw following exposure to bisphosphonates like Fosamax. Understanding the long-term outcome of this condition requires a careful consideration of the patient's history of medication use, moving from a broad awareness of health science to a precise occupational or therapeutic exposure concern.

Understanding Fosamax and Its Association with Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a known adverse effect associated with bisphosphonate use, including Fosamax. ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Long-Term Prognosis and Quantitative Risk Estimates

Regarding the long-term prognosis of ONJ after Fosamax exposure, evidence from a cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink provides quantitative risk estimates. Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This suggests that while the relative risk increases with longer exposure, the absolute risk of developing ONJ remains small, and the risk decreases after stopping treatment. The mechanistic pathways linking Fosamax to ONJ involve jawbone-specific responses to bisphosphonate therapy. Current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). This research highlights the unique biology of the jawbone that may predispose it to complications from bisphosphonate exposure.

Risk Communication and Clinical Considerations

In terms of risk communication, the prescribing information for Fosamax includes warnings about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the adequacy of these warnings may be questioned given the variability in onset and the potential for recurrence upon rechallenge. The label does not provide specific guidance on monitoring for ONJ beyond general risk factor identification. For affected patients, prognosis-related considerations include the potential for symptom relief after discontinuation, but also the possibility of recurrence if treatment is resumed. The timeline between exposure and documented harm can range from one day to several months after starting the drug, and the risk increases with longer duration of use. Patients with known risk factors, such as poor oral hygiene or pre-existing dental disease, may be at higher risk and should be counseled accordingly. In summary, while Fosamax is effective for osteoporosis treatment, its use carries a risk of ONJ, particularly with prolonged exposure. The prognosis for ONJ after Fosamax exposure is generally favorable with discontinuation, but recurrence is possible. Absolute risks remain low, and the risk diminishes after stopping treatment. Clinicians should weigh the benefits of Fosamax against the risk of ONJ, especially in patients with additional risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the long-term prognosis for osteonecrosis of the jaw after Fosamax exposure?

The long-term prognosis for ONJ after Fosamax exposure is generally favorable with discontinuation of the drug. Most patients experience relief of symptoms after stopping Fosamax, but a subset may have recurrence if rechallenged with the same or another bisphosphonate. Absolute risks remain low, approximately 0.05% after 5 years, and diminish after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/).

How does the duration of Fosamax use affect the risk of ONJ?

The risk of ONJ increases with longer duration of Fosamax use. Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). However, absolute risks remain low, and the risk decreases after stopping treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.